Skip to content

Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJDementia
    • VJRegenmed
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    MDS 2023
    EAN 2023
    AHS 2023
    CMSC 2023
    ESOC 2023
    AAN 2023
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Tominersen

Update on huntingtin-lowering strategies under investigation for Huntington’s disease 4:14
Update on huntingtin-lowering strategies under investigation for Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
The impact of wild-type HTT suppression on brain function 0:50
The impact of wild-type HTT suppression on brain function
Ann Morgan et al. • 16 Sep 2022
Huntingtin lowering: what level of wildtype protein knockdown is safe? 2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
Moving forwards after disappointing data in the Huntington’s disease space 1:05
Moving forwards after disappointing data in the Huntington’s disease space
Patrick Weydt • 23 Sep 2022
Ongoing trials with importance for Huntington’s disease 4:24
Ongoing trials with importance for Huntington’s disease
Jee Bang • 4 Apr 2022
Huntingtin-lowering strategies for Huntington’s disease 2:56
Huntingtin-lowering strategies for Huntington’s disease
Anne Rosser • 18 Jun 2021
Treatment of neurodegenerative disorders at EAN 2021 2:08
Treatment of neurodegenerative disorders at EAN 2021
Tiago Outeiro • 18 Jun 2021
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs 4:28
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs
Tiago Mestre • 26 Apr 2021
ASO tominersen for Huntington’s disease in Phase III trials 2:20
ASO tominersen for Huntington’s disease in Phase III trials
Edward Wild • 4 Sep 2020
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy